118 related articles for article (PubMed ID: 22704161)
21. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
22. [HER2-positive breast cancer: standard and double targeted therapy].
Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
Milano G; Chamorey E; Ferrero JM
JAMA Oncol; 2016 Jan; 2(1):21-2. PubMed ID: 26540493
[No Abstract] [Full Text] [Related]
24. Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients.
Hacioglu B; Akin S; Sever AR; Altundag K
Future Oncol; 2015 Sep; 11(18):2495-7. PubMed ID: 26278702
[No Abstract] [Full Text] [Related]
25. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
26. [Not Available].
Gonçalves A
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
[TBL] [Abstract][Full Text] [Related]
27. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
28. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
Wolff AC; Hammond ME; Hayes DF
J Natl Cancer Inst; 2012 Jun; 104(12):957-8. PubMed ID: 22581974
[No Abstract] [Full Text] [Related]
29. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
30. Hints of future progress for HER-2 breast cancer.
Twombly R
J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
[No Abstract] [Full Text] [Related]
31. Pertuzumab (Perjeta) for preoperative use in HER2-positive breast cancer.
Med Lett Drugs Ther; 2013 Dec; 55(1431):98-9. PubMed ID: 24322664
[No Abstract] [Full Text] [Related]
32. Weighing the options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer.
Lin NU
J Clin Oncol; 2015 May; 33(14):1530-3. PubMed ID: 25847924
[No Abstract] [Full Text] [Related]
33. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
[TBL] [Abstract][Full Text] [Related]
34. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
Zardavas D; Fouad TM; Piccart M
Breast; 2015 Nov; 24 Suppl 2():S143-8. PubMed ID: 26255196
[TBL] [Abstract][Full Text] [Related]
35. HER2-positive breast cancer.
Loibl S; Gianni L
Lancet; 2017 Jun; 389(10087):2415-2429. PubMed ID: 27939064
[TBL] [Abstract][Full Text] [Related]
36. Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can We Understand It Better?
Loi S; Savas P
J Clin Oncol; 2016 Feb; 34(6):521-3. PubMed ID: 26755511
[No Abstract] [Full Text] [Related]
37. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Harbeck N
Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
[TBL] [Abstract][Full Text] [Related]
38. Reply to L. Cabel et al.
Fehrenbacher L; Capra A; Habel L
J Clin Oncol; 2015 Jan; 33(3):292-3. PubMed ID: 25512452
[No Abstract] [Full Text] [Related]
39. A step towards a HER2-positive breast cancer super family.
von Minckwitz G
Lancet Oncol; 2015 Jul; 16(7):745-6. PubMed ID: 26092817
[No Abstract] [Full Text] [Related]
40. Dual HER2 inhibition and paclitaxel in metastatic breast cancer.
Brower V
Lancet Oncol; 2015 Feb; 16(2):e57. PubMed ID: 25577955
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]